Business
Nuwellis Announces Termination of REVERSE-HF Clinical Trial to Focus on Strategic Growth in Outpatient Heart Failure Care
WHOWHATWHENWHYNuwellis, Inc.Termination of theREVERSE-HF clinicaltrialJuly 17, 2025To redirect resources towardoutpatient markets where scalableimpact is highest. MINNEAPOLIS, July 17, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. today announced the termination of its REVERSE-HF clinical trial, a randomized post-market trial evaluating ultrafiltration vs. IV loop diuretic therapy for fluid management in hospitalized heart failure patients. This decision reflects the company’s strategic commitment to
About this update from Nuwellis, Inc.
[{"type":"image","alt":"Nuwellis, Inc.","displaySize":"","headline":null,"caption":"Nuwellis, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":72,"url":"https://media.zenfs.com/en/globenewswire.com/d2460037586c5d451999b7d63383d34b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/epm_zxode7LAVlWVBg62FQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwMTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/d2460037586c5d451999b7d63383d34b","width":300,"height":72}},"lazy":false},{"type":"table","headerItems":[],"items":[{"val":[{"style":"max-width:25%;width:25%;min-width:25%;border-top:solid black 1pt;border-right:solid black 1pt;border-bottom:solid black 1pt;border-left:solid black 1pt;text-align:center;vertical-align:middle;vertical-align:middle;","val":[{"type":"text","content":"WHO","length":3,"tagName":"p","attribs":{}}]},{"style":"max-width:25%;width:25%;min-width:25%;border-top:solid black 1pt;border-right:solid black 1pt;border-bottom:solid black 1pt;border-left:solid black 1pt;text-align:center;vertical-align:middle;vertical-align:middle;","val":[{"type":"text","content":"WHAT","length":4,"tagName":"p","attribs":{}}]},{"style":"max-width:25%;width:25%;min-width:25%;border-top:solid black 1pt;border-right:solid black 1pt;border-bottom:solid black 1pt;border-left:solid black 1pt;text-align:center;vertical-align:middle;vertical-align:middle;","val":[{"type":"text","content":"WHEN","length":4,"tagName":"p","attribs":{}}]},{"style":"max-width:25%;width:25%;min-width:25%;border-top:solid black 1pt;border-right:solid black 1pt;border-bottom:solid black 1pt;border-left:solid black 1pt;text-align:center;vertical-align:middle;vertical-align:middle;","val":[{"type":"text","content":"WHY","length":3,"tagName":"p","attribs":{}}]}]},{"val":[{"style":"border-top:solid black 1pt;border-right:solid black 1pt;border-bottom:solid black 1pt;border-left:solid black 1pt;text-align:center;vertical-align:middle;vertical-align:middle;","val":[{"type":"text","content":"Nuwellis, Inc.","length":14,"tagName":"p","attribs":{}}]},{"style":"border-top:solid black 1pt;border-right:solid black 1pt;border-bottom:solid black 1pt;border-left:solid black 1pt;text-align:center;vertical-align:middle;vertical-align:middle;","val":[{"type":"text","content":"Termination of theREVERSE-HF clinicaltrial","length":44,"tagName":"p","attribs":{}}]},{"style":"...